VYNE vs ORGO

For growth investors, Organogenesis Holdings Inc.

(ORGO) is the stronger pick with 17. 0% revenue growth year-over-year, versus 13. 8% for VYNE Therapeutics Inc. (VYNE). Organogenesis Holdings Inc. (ORGO) offers the better valuation at 15. 8x trailing P/E, making it the more compelling value choice. Analysts rate Organogenesis Holdings Inc. (ORGO) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Organogenesis Holdings Inc.

(ORGO) delivered a total return of -87. 7%, compared to -98. 9% for VYNE Therapeutics Inc. (VYNE). Over 10 years, the gap is even starker: ORGO returned -75. 7% versus VYNE's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), VYNE Therapeutics Inc.

(VYNE) is the lower-risk stock at 0. 71β versus Organogenesis Holdings Inc. 's 1. 83β — meaning ORGO is approximately 156% more volatile than VYNE relative to the S&P 500.

By revenue growth (latest reported year), Organogenesis Holdings Inc.

(ORGO) is pulling ahead at 17. 0% versus 13. 8% for VYNE Therapeutics Inc. (VYNE). On earnings-per-share growth, the picture is similar: Organogenesis Holdings Inc. grew EPS 1600% year-over-year, compared to 34. 0% for VYNE Therapeutics Inc.. Over a 3-year CAGR, ORGO leads at 7. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Organogenesis Holdings Inc.

(ORGO) is the more profitable company, earning 6. 6% net margin versus -46. 5% for VYNE Therapeutics Inc. — meaning it keeps 6. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ORGO leads at 10. 0% versus -52. 2% for VYNE. At the gross margin level — before operating expenses — VYNE leads at 96. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, VYNE Therapeutics Inc.

(VYNE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 71)). Organogenesis Holdings Inc. (ORGO) carries a higher beta of 1. 83 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (VYNE: -100. 0%, ORGO: -75. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: VYNE is a small-cap quality compounder stock; ORGO is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.